Literature DB >> 2932217

Metabolism and disposition of menogaril (NSC 269148) in the rabbit.

P Dodion, M J Egorin, K L Engisch, N R Bachur.   

Abstract

We have investigated the metabolism and disposition, in rabbits, of menogaril (7-OMEN), a new anthracycline antibiotic recently introduced into clinical trials. 7-OMEN was administered by rapid i.v. injection at a dosage of 2.5 mg/kg. 7-OMEN and metabolites were assayed by high performance liquid chromatography. Plasma concentrations of 7-OMEN declined in biexponential fashion with a terminal half-life of 2.7 h. The area under the plasma concentration versus time curve was 1.3 microM X h. The systemic clearance of 7-OMEN was 57.6 ml/min/kg. No metabolite of 7-OMEN was detected in plasma. At 8 h after treatment, the cumulative urinary and biliary excretions of 7-OMEN equivalents amounted to 1.3 and 3.4% of the total administered dose, respectively. 7-OMEN was the predominant fluorescent compound in urine, but four metabolites were also seen. In bile, 7-OMEN represented only 9.6% of the cumulative excretion and six metabolites were observed. Among the organs, lungs contained the highest concentrations of parent drug. Substantial concentrations of metabolites were observed in the kidneys, liver, duodenum, and small intestine. Three of the observed metabolites of 7-OMEN have been tentatively identified as N-demethylmenogaril, 7-deoxynogarol, and N-demethyl-7-deoxynogarol.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2932217

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Tolerance of full dose menogaril (NSC 269148) in patients with abnormal hepatic and renal function.

Authors:  B A Conley; M J Egorin; V Sinibaldi; D A Van Echo
Journal:  Invest New Drugs       Date:  1990-11       Impact factor: 3.850

2.  Human autopsy-tissue distribution of menogaril and its metabolites.

Authors:  D J Stewart; D Grewaal; R M Green; R Goel; N Mikhael; V A Montpetit; D Redmond; R Earhart
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Pharmacokinetics of 7-con-O-methylnogarol in patients with solid tumors.

Authors:  M L Zanette; U Tirelli; R Sorio; D Zadro; F Figoli; S Monfardini; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.